海南医科大学学报

目的:观察肠镜下植入氟尿嘧啶缓释剂治疗结肠癌疗效及安全性。方法:对80例诊断为结肠癌的患者进行临床分组观察治疗,观察组手术前在肠镜下植入氟尿嘧啶缓释剂,对照组常规手术操作。观察两组术后毒副反应、肿瘤复发情况以及3年生存率。结果:毒副作用方面,两组术后白细胞(WBC)、谷丙转氨酶(ALT)、血肌酐(Scr)均有一定程度的上升,但两组比较,差异无统计学意义(P>0.05)。肿瘤复发方面,Dukes C期患者,观察组复发率明显低于对照组(P<0.05)。生存期方面,1年生存率方面,两组无统计学差异(P>0.05),2年及3年生存期,观察组明显高于对照组(P<0.05)。结论:肠镜下植入氟尿嘧啶缓释剂治疗结肠癌毒副反应低,能够有效减低Dukes C期患者局部肿瘤复发率,提高患者2、3年临床生存率。

Objective:To observe effect of implantation of fluorouracil sustained-release agent under colonoscopy on treatment of colon cancer.Methods:Eighty patients who were diagnosed as colon cancer were randomly divided into control group and observation group.Patients in observation were implanted with fluorouracil sustained-release agent under colonoscopy before surgery,while patients in control group had only routine surgery.Postoperative toxicity,tumor recurrence,and 3-year survival rate were observed and compared.Results:Toxic and side-effect,postoperative white blood cell,alanine aminotransferase,serum creatinine were increased more or less,but the difference was not significant(P>0.05).The relapse rate of observation group was significantly lower than that of control group(P<0.05).There was no significant difference in 1-year survival rate,but 2and 3-year survival was significantly higher in observation group than control group(P<0.05).Conclusion:Implantation of fluorouracil sustained-release agent under colonoscopy is of few side effect.It can effectively reduce Dukes C with local tumor recurrence rate and improve the 2,3-year clinical survival rate.